EMAIL THIS PAGE TO A FRIEND

Science advances

Syrosingopine sensitizes cancer cells to killing by metformin.


PMID 28028542

Abstract

We report that the anticancer activity of the widely used diabetic drug metformin is strongly potentiated by syrosingopine. Synthetic lethality elicited by combining the two drugs is synergistic and specific to transformed cells. This effect is unrelated to syrosingopine's known role as an inhibitor of the vesicular monoamine transporters. Syrosingopine binds to the glycolytic enzyme α-enolase in vitro, and the expression of the γ-enolase isoform correlates with nonresponsiveness to the drug combination. Syrosingopine sensitized cancer cells to metformin and its more potent derivative phenformin far below the individual toxic threshold of each compound. Thus, combining syrosingopine and codrugs is a promising therapeutic strategy for clinical application for the treatment of cancer.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SML1908
Syrosingopine, ≥95% (HPLC)
C35H42N2O11